New drug rocbrutinib takes on tough lymphoma in major trial
NCT ID NCT07377578
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests a new drug called rocbrutinib against other targeted therapies for mantle cell lymphoma, a type of blood cancer. About 394 adults whose cancer has returned or not responded to previous treatment will be randomly assigned to receive rocbrutinib or another BTK inhibitor. The study aims to see if rocbrutinib can delay cancer progression better than current options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rocbrutinib (a targeted drug that blocks a protein called BTK to slow cancer growth)
What this could lead to
If successful, rocbrutinib could offer a more effective and safer treatment option for people with mantle cell lymphoma that has returned or not responded to prior therapy.
What could go wrong
This is an early-stage Phase 3 trial, so results are not yet known. The drug may not work better than existing options, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Guangxi Medical University
NOT_YET_RECRUITINGNanning, Guangxi, 530021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact